Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Council Clears Public Knowledge Filing for MabCampath in T-PLL
Japan’s health ministry council has endorsed a public knowledge-based filing to add T-cell prolymphocytic leukemia (T-PLL) as an indication for Sanofi’s cancer therapy MabCampath (alemtuzumab). The Ministry of Health, Labor and Welfare’s Council on Unapproved Drugs and Indications with Unmet…
To read the full story
Related Article
- MHLW Seeks Sponsors for 6 High-Need Unapproved, Off-Label Drugs
July 2, 2026
- MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
- Japan Panel Backs Boehringer’s IPF Drug, Moderna COVID Vaccine
April 28, 2026
- Japan Identifies 28 New “Drug Loss” Products from 2021-23 Approvals
April 7, 2026
- MHLW Seeks Sponsors to Develop 8 “Drug-Loss” Products
March 2, 2026
- MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
- MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
- Industry Calls for More Tailored Govt Support on Drug Loss Product Development
July 16, 2025
- J-ENTRY Consortium Steps Up to Develop Two “Drug Loss” Products
July 9, 2025
- MHLW Seeks Development Sponsors for 5 “Drug Loss” Products
May 21, 2025
- MHLW to Help Match Domestic Firms with Overseas Originators to Fight Drug Loss
May 12, 2025
- MHLW Council Deems 11 “Loss” Products as Medically Highly Necessary
May 12, 2025
- Japan to Buttress Regulatory Communication Efforts for Drug Originators Overseas
April 25, 2025
- Japan Picks 14 “Loss” Products as Drugs with Highest Priority for Development
April 2, 2025
- Japan Gets Down to the Business of Solving Drug Loss, New Scheme Begins with 78 Meds
November 26, 2024
- MHLW Lists Up 78 Drug-Loss Assets, Asks Makers to Report Any Hurdles in Development
October 28, 2024
- MHLW Proposes New Scheme for Development Requests to Fight Drug Loss
July 8, 2024
REGULATORY
- MHLW Seeks Sponsors for 6 High-Need Unapproved, Off-Label Drugs
July 2, 2026
- MHLW Orders Label Revisions for Four Pediatric Antibiotics
July 2, 2026
- LDP Lawmakers Seek Separate Drug Pricing Measures for Inflation
July 2, 2026
- Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
- Govt Presents Growth Strategy Draft Ahead of July Approval
July 1, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…